Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | amiloride sensitive cation channel acid sensing ion channel pituitary | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | Na+ channel, amiloride sensitive | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | amiloride sensitive cation channel 4 A | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | Na+ channel, amiloride sensitive | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | Na channel amiloride sensitive | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | amiloride-sensitive sodium channel-related | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | sodium channel nonvoltage gated 1 alpha | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | protein vprbp | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | acid sensing ion channel 4 pituitary | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | FMRFamide-gated Na+ channel | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | sodium channel nonvoltage gated 1 alpha | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | amiloride sensitive cation channel | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | amiloride-sensitive sodium channel-related | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | amiloride sensitive cation channel 4 A | 0.0056 | 0 | 0.5 |
Onchocerca volvulus | 0.0086 | 1 | 1 | |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | amiloride-sensitive sodium channel-related | 0.0056 | 0 | 0.5 |
Loa Loa (eye worm) | amiloride-sensitive sodium channel family protein | 0.0086 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | protein vprbp | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | amiloride sensitive cation channel 4 A | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | amiloride sensitive sodium channel | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | FMRFamide activated amiloride sensitive sodium | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | amiloride sensitive cation channel 4 A | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | amiloride-sensitive sodium channel-related | 0.0056 | 0 | 0.5 |
Echinococcus granulosus | Na channel amiloride sensitive | 0.0056 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IZ (functional) | = 21.06 mm | Antibacterial activity against Escherichia coli MTCC-725 assessed as zone of inhibition at 1 ug/ml | ChEMBL. | 25019476 |
MLD (ADMET) | = 2.26 g/Kg | Toxicity in po dosed Swiss albino mouse after 72 hrs | ChEMBL. | 25019476 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.